Publications

5808 Results

SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics

Authors
P Lara;J Moon;P Hesketh;M Redman;SK Williamson;F Hirsch;P Mack;D Gandara
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 8040); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Lung
Study Number(s)
S0709

SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)

Authors
JC Yao;K Guthrie;C Moran;J Strosberg;MH Kulke;J Ang Chan;N Loconte;R McWilliams;EM Wolin;BI Mattar;S McDonough;H Chen;C Blanke;HS Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s, 2015 (suppl; abstr 4004); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S0518

SWOG S1115: randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX inpatients with metastatic pancreatic cancer after prior chemo- therapy

Authors
V Chung;S McDonough;PA Phillip;D Backlund Cardin;A Wang-Gillam;L Hui;A Lowy;K Guthrie;C Blanke;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4119); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S1115

Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors from SWOG S1008

Authors
H Greenlee;D Lew;J Pierce;L Hansen;V Newman;J Korner;A Sayegh;L Frehrenbacher;S Lo;J Klemp;K Rinn;J Robertson;J Unger;J Gralow;K Albain;R Krouse;C Fabian
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 9572); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Cancer Survivorship
Study Number(s)
S1008

SWOG S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX), capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC)

Authors
CG Leichman;S McDonough;S Smalley;K Billingsley;H Lenz;A Hezel;M Velasco;M Beldner;K Guthrie;C Blanke;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl;abstr 3516); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S0713

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140)

Authors
M Chavez-Macgregor;W Barlow;L Pusztai;MP Goetz;P Rastogi;P Ganz;EP Mamouns;S Paik;H Bandos;J Gralow;D Lew;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS637); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Breast
Study Number(s)
S1207

SWOG 1107: Parallel randomized phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (pts) with advanced papillary renal cell carcinoma (pRCC)

Authors
P Twardowski;M Plets;ER Plimack;N Aggarwal;C Tangen;N Vogelzang;IM Thompson;PN Lara
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4523); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
S1107

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307(NCT00127205)

Authors
J Gralow;W Barlow;A Paterson;D Lew;A Stopeck;D Hayes;D Hershman;M Schubert;M Clemons;C Van Poznak;EC Dees;JN Ingle;C Falkson;A Elias;M Messino;J Margolis;S Dakhil;H Chew;R Livingston;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 33:5s, 2015 (suppl; abstr 503);American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Breast
Study Number(s)
S0307

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)

Authors
M Dickler;WT Barry;CT Cirrincione;M Ellis;M Moynahan;H Rugo;B Schneider;D Tripathy;C Hudis;E Winer
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 501); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Authors
R Kim;S McDonough;A El-Khoueiry;T Bekaii-Saab;K Guthrie;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS4142); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), TIPS, poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S1310